BOSTON, Oct. 19, 2026 — TEAMFund, a 501(c)(3) Public Charity and a For-Profit Impact Fund whose mission is to enhance patient access to medical technology in low-resource settings, announced at The AdvaMed MedTech Conference, the release of this year’s Annual Impact Report. TEAMFund’s seven portfolio companies (Jana Care, Forus Health, Tricog Health, MediBuddy, EchoNous, Vezeeta, Qure.ai), performed 49MM patient services and contributed to the needs of 37MM unique patients over the past year.
AOADx Logo
During a presentation in Boston, Tim Ring, former C. R. Bard CEO and TEAMFund Co-Founder, said “We are proud that our companies, in aggregate, are now reaching 37MM unique patients per year, a 30% increase over last year. Impact investors today are asking for ‘performance + impact,’ and that was precisely the premise on which TEAMFund was founded. With Fund I now returning capital to our Limited Partners, we are seeing that health impact and investment performance can reinforce one another. These impact numbers are all about the hard work and innovation of our seven companies and their employees.”
Also at the MedTech Conference, TEAMFund awarded its Global Health Innovation Award to AOA Dx, which is pioneering the use of lipidomics to detect early-stage cancers through a non-invasive blood test, starting with ovarian cancer. Ovarian cancer disproportionately impacts women in low- and middle-income countries, where limited screening infrastructure, imaging, and specialist expertise mean most cases are diagnosed at advanced stages. Simple, affordable, blood-based tests can help frontline health workers screen at-risk or symptomatic women and prioritize referrals, improving early detection and outcomes without costly infrastructure. This is TEAMFund’s ninth award to a female founder/CEO.
A few highlights from the Annual Impact Report:
*CUMULATIVELY 203MM PATIENT SERVICES AND 144MM UNIQUE PATIENTS SERVED, *67% OF PATIENTS WERE SERVED IN INDIA OR AFRICA, and *25,825 NEW PROVIDERS TRAINED LAST YEAR.
A complete copy of the Report can be found on TEAMFund’s website www.teamfundhealth.org.
ABOUT AOA DX
AOA Dx, led by CEO and Co-Founder Oriana Papin-Zoghbi, is transforming early cancer detection with a proprietary multi-omics liquid biopsy platform that integrates lipid, metabolite, and protein biomarkers with machine learning. The company’s lead test, AKRIVIS GD™, is an investigational blood test designed to detect ovarian cancer early in symptomatic women, addressing a critical diagnostic gap in one of the deadliest cancers affecting women. AOA Dx is the ninth winner of TEAMFund’s Annual Global Health Innovation Award and the ninth consecutive female founder. www.aoadx.com
ABOUT TEAMFUND
TEAMFund (Transforming Equity and Access in MedTech), is an organization that combines a Non-Profit with an impact fund Limited Partnership, both having a shared aim to expand access to affordable, appropriate, and sustainable medical technologies that address unmet health needs in low-resource, underserved settings across the globe. TEAMFund is co-founded and co-chaired by Timothy Ring, former Chairman and CEO of C.R. Bard, and Kathryn Gleason, former senior partner at Morgan Lewis. TEAMFund counts among its supporters over 20 major MedTech and healthcare companies worldwide. www.teamfundhealth.org
$90 million financing committed by Spice Expeditions, WashU and Moore and $50 million of bond proceeds to fund the scaling of profitable lending and launches of new products
MANILA, Philippines, Oct. 19, 2026 — Salmon Group, a technology-driven banking and lending platform in the Philippines, today announces that it secured additional $140 million of financing to continue its growth in the Philippines.
Proceeds from the financing round will fund the scaling of profitable lending (Salmon Credit Line and in-store lending) and nationwide roll-out of new products, including motorcycle and MSME lending.
Salmon co-founders (from left to right: George Chesakov, Pavel Fedorov and Raffy Montemayor) in front of Nasdaq’s headquarters in Times Square, New York.
In less than four years of operations, Salmon has become one of the fastest-growing technology companies in the Philippines, operating through a BSP-licensed bank, Salmon Bank (Rural Bank) and an SEC-licensed financing company, Salmon Finance.
Today, the companies in Salmon Group serve millions of Filipinos through its Salmon app – one of the highest rated financial services apps in the Philippines with 9 million downloads, 4.8 rating on App Store and Google Play, 99.9% uptime, and dedicated 24/7 customer support. Through the AI-powered credit engine of Salmon Finance, the group’s financing arm, Salmon is able to serve customers with limited credit history and provide credit decisions within minutes.
“Everyday financial services come with unnecessary friction for many Filipinos. We’re removing these barriers and building innovative products with the reliability and security customers expect in today’s world,” said Pavel Fedorov, co-founder of Salmon. “We are doubling down on the opportunity in the Philippines as we believe deeply in its scale and in the importance of focus to deliver a differentiated execution. This financing lets us do more: extend banking and credit access to more Filipinos, roll out new products, and keep raising the bar for the financial services industry in the country. We are grateful to our existing investors for backing the next stage of our mission.”
ABOUT SALMON
Salmon Group is a technology-driven financial services holding company building a banking and lending platform across Southeast Asia, starting with the Philippines. The Group operates a BSP-licensed bank, Salmon Bank (Rural Bank) Inc.; an SEC-licensed financing company, Salmon Finance Inc.; and a growing suite of financial products – all delivered through the Salmon app, a modern money app built for everyday Filipinos. Founded in July 2022 by banking and technology veterans Pavel Fedorov, George Chesakov, and Raffy Montemayor, Salmon is backed by leading US venture investors, IFC (World Bank Group), ADQ/Lunate, Antler as well as prominent Filipino investors. The Salmon app is rated 4.8 in both the App Store and Google Play, one of the highest ratings for a financial services app in the Philippines.
WASHINGTON, Oct. 16, 2026 — Lightview Capital announced a strategic growth investment in Thorn Run Partners (TRP), a Top 10 ranked national, bipartisan government relations firm. The partnership will serve as a growth catalyst, designed to enhance TRP’s service offerings, scale capabilities across policy verticals and geographies, and expand the firm’s pool of talent.
Thorn Run Partners – founded by Andrew Rosenberg and Chris Lamond in 2010 – has scaled to serving over 300 clients today. In tandem with the investment, Thorn Run Partners will actively pursue synergistic, like-minded add-on acquisitions and new hires to complement its existing platform and further cement its position as a dominant market leader.
“We couldn’t be prouder of the team we’ve assembled at Thorn Run Partners, not to mention the uniquely collaborative culture we’ve built around them,” said co-founder Andrew Rosenberg. “And I am excited that our partners at TRP are equally enthusiastic about, and heavily invested in, the success of this new growth moment for the firm.”
“This presents an exciting opportunity for TRP to take our client service to a new level,” said co-founder Chris Lamond. “The Lightview partnership will provide us the resources to add even more talent and to build an even larger, more comprehensive platform that will allow us to serve our current and future clients even better than we do today.”
“Thorn Run’s sustained growth, exemplary client roster, innovative mindset, and reputation for employing subject matter experts make them a compelling platform investment for us,” said Conor Mullett, Co-Founder and Managing Director of Lightivew Capital. “In TRP, we found a firm that is both committed to client service today and has a real vision for tomorrow for how to develop a synergistic suite of new offerings that will cement their position among the top government affairs firms in the country. We are thrilled to partner with Chris, Andrew, and the TRP team to expand their footprint.”
BrightTower acted as a buyside advisor as part of the transaction.
About Thorn Run Partners
Founded in January 2010 by veteran lobbyists Andrew Rosenberg and Chris Lamond, who previously served as staffers to Senators Edward M. Kennedy (D-MA) and Fred Thompson (R-TN), respectively, Thorn Run Partners is a full-service, +60-person government relations, policy, and strategic communications firm with offices in Washington, DC, Portland, OR, and Los Angeles, CA. TRP has been consistently recognized as a Top 10 lobbying firm by respected publications including Politico, The Hill, and Bloomberg.
About Lightview Capital
Lightview Capital is a leading private equity firm focused on investing in founder-owned companies in the business services and tech-enabled services industries. Lightview partners with its portfolio companies by providing deep industry knowledge, insightful experience, and active resources to unlock growth and drive value.
Leadership transition positions the company for its next phase of growth as it extends autonomous, attack-validated security from an organization’s own attack surface to the vendors it depends on.
BOSTON, Oct. 16, 2026 — SpartanX, the autonomous offensive security company, announced the appointment of Erik Hardy as Chief Executive Officer and the launch of Vendor Management, a new capability that brings real, attack-validated security posture to third-party risk. Company founder Diego Spahn moves into the role of Co-Founder and Chief Technology and Product Officer and remains on the board.
Hardy, previously President and Chief Operating Officer, steps into the CEO role as part of a broader expansion of the leadership team. Co-Founder Alejandro Aguirre Soto becomes Senior Vice President of Engineering, and Co-Founder Martin Voelk becomes Chief Research Officer. The changes follow a period of rapid growth and are designed to put each leader where they can have the greatest impact as the company scales.
The announcement coincides with the launch of Vendor Management, among the most significant additions to the SpartanX platform to date. Third-party breaches remain one of the hardest risks for security teams to measure, and most programs still rely on self-reported questionnaires and point-in-time audits. Vendor Management takes a different approach: organizations invite their vendors onto SpartanX, each vendor runs on its own workspace and chooses which assets to share, and the customer sees that vendor’s validated risk posture, grounded in continuous, autonomous testing rather than a checklist. A strict privacy boundary ensures each organization sees a vendor’s posture and shared-asset scores while the vendor’s underlying findings and internal data stay entirely its own.
Olympus, the release that carries Vendor Management, also expands the platform’s core offensive capabilities. SpartanX added hundreds of new specialized AI agents covering a wider range of enterprise applications and technologies, alongside new retesting that lets teams confirm whether code and mobile findings have actually been fixed. Together, the additions deepen the platform’s ability to prove which exposures are genuinely exploitable, across more of an organization’s environment.
“SpartanX has built something the market has never seen: an autonomous platform that attacks the way a real adversary would, at a scale no human team can match,” said Erik Hardy, Chief Executive Officer of SpartanX. “Our customers are not just finding vulnerabilities, they are proving which ones actually matter. With Vendor Management, we extend that same proof to the one part of the attack surface every company worries about and almost no one can measure: their vendors. I am honored to lead this team into its next chapter.”
SpartanX is pioneering the category of Autonomous Exposure Management. The leadership transition and the launch of Vendor Management mark the start of the company’s next phase as it brings autonomous, attack-validated security to a growing roster of enterprise customers.
About SpartanX
SpartanX is an autonomous offensive security company. Its platform deploys fleets of specialized AI agents to continuously test an organization’s attack surface across web, API, network, cloud, identity, and AI systems, the way a real attacker would, and to prove which exposures are genuinely exploitable. SpartanX is pioneering the category of Autonomous Exposure Management and is backed by Venture Guides. Learn more at spartanx.ai.
NEW YORK, Oct. 16, 2026 — Functional medicine physician Dr. Ruth Johnson, an investor in RunPractice, has experienced a familiar problem in her Midtown Manhattan practice: separate tools and vendors handling different parts of the business, with her team left to connect them.
RunPractice brings digital infrastructure, AI agents, and growth operations together in one managed system. Websites, booking, patient communication, payments, and marketing work together, with one partner responsible for implementation and ongoing management.
Dr Johnson & her team
Dr Johnson
The approach connects the patient relationship from the first inquiry through booking and follow-up. AI agents support routine administrative tasks while practice teams stay in control of interactions that need human attention.
Dr. Johnson uses RunPractice in her own clinical practice. That experience helps guide product development around the operational challenges physicians and their teams face every day.
The goal is straightforward: less time coordinating the business, more time with patients.
RunPractice is a health technology company that connects and manages the business behind independent medical practices. Its model brings digital infrastructure, AI agents, and growth operations together to support patient acquisition, practice operations, and ongoing patient relationships.
New actively managed ETF seeks to provide exposure to companies developing humanoid robots and the technologies powering their advancement.
LAS VEGAS, Oct. 16, 2026 — Rareview Capital LLC and Tuttle Capital Management today announced the launch of the Tuttle – Rareview Humanoid Robotics ETF (Symbol: HOID), an actively managed exchange-traded fund seeking capital appreciation through investments in companies developing humanoid robots and the technologies that make them possible.
HOID provides a targeted approach to the humanoid robotics ecosystem, extending beyond robot manufacturers to include the technologies and components supporting their development. The strategy considers both the “Brains“, artificial intelligence, software, and semiconductors, and the “Body“, sensors, actuators, batteries, and other essential components.
“Artificial intelligence has shown how quickly a new technology can evolve and reshape entire industries. We believe humanoid robotics is entering a similar period of development, with meaningful advances likely to unfold over the next decade,” said Neil Azous, Founder and Chief Investment Officer of Rareview Capital. “We’re excited to bring investors an opportunity to participate in that evolution through a strategy that looks beyond the robots themselves to the companies developing the technologies that make them possible.”
The fund may invest in U.S. and international companies, including those in commercial production and those developing fully functional prototypes progressing toward commercialization. Portfolio weights are rebalanced at least quarterly.
Matthew Tuttle, Chief Executive Officer of Tuttle Capital Management, sub-adviser and co-portfolio manager of HOID, said, “A humanoid robot has a brain and a body. The brain is chips, software and AI models. The body is actuators, sensors and batteries. HOID invests across both. Neil Azous and the Rareview Capital team and I built this fund to follow the whole supply chain, from the companies building the robots to the ones making the parts inside them.”
Rareview Capital LLC is a registered investment adviser and ETF sponsor specializing in goals-based investment strategies. The firm’s solutions are available through ETFs, sub-advisory and dual-contract arrangements, model portfolios, or direct client accounts. Rareview Capitalis headquartered in Las Vegas, Nevada. For more information, please visit www.rareviewcapital.com or contact the firm at 212-475-8664.
About Tuttle Capital Management
Tuttle Capital Management is a leading issuer of thematic ETFs that allow investors to capitalize on shifting market dynamics. The firm is known for its active management approach and its ability to construct portfolios around emerging trends, spanning actively managed thematic equity ETFs, the Income Blast series of weekly-distribution ETFs, and rules-based index ETFs developed in collaboration with third-party index providers. For more about Tuttle Capital’s full suite of funds, visit www.tuttlecap.com.
Carefully consider the Fund’s investment objectives, risk factors, charges and expenses before investing. This and additional information can be found in the Fund’s full and summary prospectus, which may be obtained by visiting rareviewcapital.com. Read the prospectus carefully before investing.
Investing involves risk, including possible loss of principal. There can be no assurance that a Fund will achieve its stated objectives. An investment in the Fund may be subject to risks which include, among others, market, interest rate, tax, liquidity, leverage, investment restrictions, operational, authorized participant concentration, no guarantee of active trading market, trading issues, active management, fund shares trading, premium/discount and liquidity of fund shares and concentration risks, all of which may adversely affect the Fund. Diversification does not ensure profits or prevent losses. Exchange-Traded Funds (ETFs) trade like stocks, are subject to investment risk, and will fluctuate in market value. Unlike mutual funds, ETF shares are not individually redeemable directly with the Fund and are bought and sold on the secondary market at market price, which may be higher or lower than the ETF’s net asset value (NAV). Transactions in shares of ETFs will result in brokerage commissions, which will reduce returns.
Affiliated Fund Risk. The Fund invests in affiliated underlying funds (the “Affiliated Funds”), unaffiliated underlying funds, or a combination of both. The Adviser, therefore, is subject to conflicts of interest in allocating the Fund’s assets among the Affiliated Funds. Humanoid Robotics Companies Risk. The Fund invests in Humanoid Robotics Companies, which may have limited product lines, markets, financial resources, or personnel and are subject to the risks of changes in business cycles, world economic growth, technological progress, and government regulation. Securities of Humanoid Robotics Companies tend to be more volatile than securities of companies that rely less heavily on technology. Humanoid Robotics Companies typically engage in significant amounts of spending on research and development, and rapid changes to the field could have a material adverse effect on a company’s operating results. China Risk. The Fund may invest in instruments that provide exposure to Chinese companies, including through investments in China A-Shares, which would subject the Fund to risks specific to China. China may be subject to considerable degrees of economic, political and social instability. China is an emerging market and demonstrates significantly higher volatility from time to time in comparison to developed markets. Concentration Risk. The Fund is concentrated in the industry or group of industries comprising the industrials, information technology and consumer discretionary sectors, collectively. ADR Risk. ADRs may be subject to some of the same risks as direct investment in foreign companies, which includes international trade, currency, political, regulatory and diplomatic risks. In a sponsored ADR arrangement, the foreign issuer assumes the obligation to pay some or all of the depositary’s transaction fees. Under an unsponsored ADR arrangement, the foreign issuer assumes no obligations and the depositary’s transaction fees are paid directly by the ADR holders. Because unsponsored ADR arrangements are organized independently and without the cooperation of the issuer of the underlying securities, available information concerning the foreign issuer may not be as current as for sponsored ADRs and voting rights with respect to the deposited securities are not passed through. Non-Diversified Risk. As a “non-diversified” fund, the Fund may hold a smaller number of portfolio securities than many other funds. To the extent the Fund invests in a relatively small number of issuers, a decline in the market value of a particular security held by the Fund may affect its value more than if it invested in a larger number of issuers. The value of the Fund Shares may be more volatile than the values of shares of more diversified funds. Non-U.S. Securities Risk. Non-U.S. securities are subject to higher volatility than securities of domestic issuers due to possible adverse political, social or economic developments, restrictions on foreign investment or exchange of securities, capital controls, lack of liquidity, currency exchange rates, excessive taxation, government seizure of assets, the imposition of sanctions by foreign governments, different legal or accounting standards, and less government supervision and regulation of securities exchanges in foreign countries. Variable Interest Risk. Exposure to VIEs may pose additional risks because the investment is made in reference to an intermediary shell company that has entered into service and other contracts with the underlying Chinese operating company to provide investors with exposure to the operating company, but does not represent equity ownership in the operating company. As a result, such investment may limit the rights of an investor with respect to the underlying Chinese operating company. VIEs allow foreign shareholders to exert a degree of control over, and obtain economic benefits arising from, the operating company without formal legal ownership.
NOT FDIC INSURED * NO BANK GUARANTEE * MAY LOSE VALUE
NEW YORK, 15 oktober 2026 — OrbiMed, een toonaangevende wereldwijde investeringsmaatschappij in de gezondheidszorg, maakt met genoegen bekend dat het voor twee nieuwe private-equityfondsen kapitaaltoezeggingen heeft ontvangen ter waarde van in totaal 3 miljard dollar: OrbiMed Private Investments X en OrbiMed Asia Partners VI.
OrbiMed Private Investments X heeft meer dan 1,9 miljard dollar opgehaald voor durfkapitaalinvesteringen in de life sciences-sector in de VS en Europa. OrbiMed Asia Partners VI heeft meer dan 1 miljard dollar opgehaald voor investeringen in groeikapitaal en durfkapitaal in de gezondheidszorg in Azië. Beide fondsen streven ernaar toonaangevende bedrijven in de gezondheidszorg op te bouwen die zich richten op biofarmaceutica, medische hulpmiddelen, diagnostiek en technologisch ondersteunde zorgdiensten.
“Er is nooit een spannender moment geweest om te investeren in innovatie binnen de life sciences”, aldus Carl Gordon, een van de managing partners bij OrbiMed. “AI, de snelle toename van nieuwe therapeutische modaliteiten en de ontwikkeling van China tot een biotechnologische grootmacht vergroten de mogelijkheden om transformatieve behandelingen te ontwikkelen. We kijken ernaar uit ondernemers te helpen deze ontwikkelingen om te zetten in toonaangevende bedrijven in de gezondheidszorg.”
OrbiMed wordt geleid door 20 partners en ondersteund door een team van meer dan 150 professionals met complementaire expertise op het gebied van bedrijfsincubatie, strategie, bedrijfsvoering en financiën. De onderneming is actief vanuit 12 locaties wereldwijd, verspreid over belangrijke markten in de gezondheidszorg.
Tot de beleggers in deze nieuwe fondsen behoort een brede groep medische instellingen, universitaire schenkingsfondsen, stichtingen, pensioenfondsen, staatsinvesteringsfondsen en family offices.
“We zijn dankbaar voor de voortdurende steun van onze vele langjarige beleggers”, aldus Carter Neild, een van de managing partners bij OrbiMed. “We zullen ons de komende jaren onvermoeibaar inzetten om aan hun hoge verwachtingen te voldoen.”
Over OrbiMed OrbiMed is een toonaangevende investeringsmaatschappij in de gezondheidszorg met meer dan 21 miljard dollar aan vermogen onder beheer. OrbiMed investeert wereldwijd in de gezondheidszorg, van start-ups tot grote multinationals, via private-equityfondsen, public-equityfondsen en royalty-/kredietfondsen. OrbiMed streeft ernaar de voorkeurspartner voor kapitaal te zijn door financieringsoplossingen op maat en de uitgebreide middelen van zijn wereldwijde team in te zetten om toonaangevende bedrijven in de gezondheidszorg op te bouwen. Het team van OrbiMed bestaat uit meer dan 150 professionals en is gevestigd in New York City, Londen, San Francisco, Shanghai, Hongkong, Mumbai, Herzliya en andere belangrijke markten wereldwijd. Ga voor meer informatie naar www.orbimed.com.
NEW YORK, 15. Oktober 2026 — OrbiMed, eine führende globale Investmentgesellschaft im Gesundheitswesen, freut sich bekannt zu geben, dass sie Zusagen in Höhe von 3 Milliarden US-Dollar für zwei neue Private-Equity-Fonds erhalten hat: OrbiMed Private Investments X und OrbiMed Asia Partners VI.
OrbiMed Private Investments X hat über 1,9 Milliarden US-Dollar eingeworben, um Investitionsmöglichkeiten im Bereich des Risikokapitals für Biowissenschaften in den USA und Europa zu nutzen. OrbiMed Asia Partners VI hat über 1 Milliarde US-Dollar eingeworben, um Investitionsmöglichkeiten im Bereich Wachstums- und Risikokapital im Gesundheitswesen in ganz Asien zu nutzen. Beide Fonds zielen darauf ab, führende Gesundheitsunternehmen aufzubauen, die sich auf Biopharmazeutika, Medizinprodukte, Diagnostik und technologiegestützte Gesundheitsdienstleistungen konzentrieren.
„Es gab noch nie einen spannenderen Zeitpunkt, um in Innovationen im Bereich der Biowissenschaften zu investieren”, sagte Carl Gordon, geschäftsführender Gesellschafter von OrbiMed. „KI, die zunehmende Vielfalt neuer Therapieansätze sowie Chinas Aufstieg zu einer führenden Macht in der Biotechnologie eröffnen neue Möglichkeiten für die Entwicklung bahnbrechender Behandlungen. Wir freuen uns darauf, Unternehmer dabei zu unterstützen, auf Grundlage dieser Fortschritte führende Unternehmen im Gesundheitswesen aufzubauen.”
OrbiMed wird von 20 Partnern geleitet sowie durch ein Team von über 150 Fachleuten mit sich ergänzenden Kompetenzen in den Bereichen Unternehmensentwicklung, Strategie, Geschäftsabläufe und Finanzen unterstützt. Das Unternehmen ist an 12 Standorten weltweit in wichtigen Gesundheitsmärkten vertreten.
Zu den Investoren dieser neuen Fonds zählen zahlreiche medizinische Einrichtungen, universitäre Stiftungsvermögen, Stiftungen, Pensionsfonds, Staatsfonds sowie Familienvermögensverwaltungen.
„Wir sind dankbar für die anhaltende Unterstützung unserer vielen langjährigen Investoren”, sagte Carter Neild, geschäftsführender Gesellschafter von OrbiMed. „Wir werden in den kommenden Jahren unermüdlich daran arbeiten, ihre hohen Erwartungen zu erfüllen.”
Informationen zu OrbiMed OrbiMed ist eine führende Investmentgesellschaft im Gesundheitswesen mit einem verwalteten Vermögen von über 21 Milliarden US-Dollar. OrbiMed investiert weltweit in Unternehmen der gesamten Gesundheitsbranche, von Start-ups bis hin zu großen multinationalen Konzernen, und nutzt dafür Private-Equity-Fonds, Fonds für börsennotierte Aktien sowie Lizenzgebühren- und Kreditfonds. OrbiMed strebt danach, der bevorzugte Kapitalgeber zu sein, und bietet maßgeschneiderte Finanzierungslösungen sowie die umfangreichen Ressourcen seines globalen Teams, um den Aufbau erstklassiger Gesundheitsunternehmen zu unterstützen. Das Team von OrbiMed mit über 150 Fachkräften ist in New York City, London, San Francisco, Shanghai, Hongkong, Mumbai, Herzliya und anderen wichtigen globalen Märkten ansässig. Weitere Informationen finden Sie auf www.orbimed.com.
Voxel51 3.0 unifies search, curation, annotation and evaluation into an end-to-end multimodal data platform.
SAN FRANCISCO, Oct. 15, 2026 — Voxel51, the data platform behind AI systems at some of the world’s leading companies, today announced Voxel51 3.0., a major expansion of its platform for building and managing physical AI datasets.
The next wave of AI is moving from the internet into the physical world. In particular, robotics is entering a phase that resembles the early days of autonomous vehicles: rapid investment, increasingly sophisticated foundation models, and an urgent need for infrastructure built around complex real-world data.
Voxel51 CEO Brian Moore adds, “We saw this play out with our customers building autonomous systems and perception models. The teams that got their data infrastructure right from the start were able to move faster. Physical AI and robotics is at that same inflection point. The companies building that foundation today are going to have a real advantage as their data and models scale.”
Voxel51 3.0 brings the core data workflows for physical AI into a single, extensible platform built for teams moving from prototype to production. New capabilities include:
Voxel51 Agent: An AI agent that works across the physical AI data loop to search, curate, label, evaluate, and chain actions into repeatable workflows.
Voxel51 Search: A persistent, hybrid search index that combines semantic search, lexical queries, and metadata filters as datasets grow.
Voxel51 Annotation: Annotation workflows across 2D, 3D, video, and multimodal data, including automated labeling with vision-language models through Agentic Labeling.
Multimodal time-series support: Synchronized visualization of sensor streams and segment-level embeddings for finding specific moments within long recordings.
Data provenance: Activity logs, sample edit history, and dataset versioning that track changes and help teams identify exactly what data went into a model.
Bring your own models: A model-agnostic architecture that supports foundation models and domain-specific models across embeddings, inference, auto-labeling, and evaluation.
Voxel51 is built for the physical AI data flywheel
Models are getting easier to build. Data work is not. And teams that consistently get models into production invest heavily in the work of systematically finding, fixing, and improving their training data. According to the State of Physical AI 2026 report, exceptional teams are three times more likely than struggling teams to spend more than half their project time on data work.
Voxel51 3.0 brings the core workflows for physical AI into an end-to-end data platform, helping teams move from raw multimodal recordings to searchable, curated training data and support active learning as models improve.
Voxel51 Agent is the most capable agent for the physical AI data flywheel. The agent draws on more than 45 MCP tools, 80+ built-in operations, and dozens of skills to chain actions across search, curation, labeling, evaluation, and other data workflows.
“Physical AI teams don’t need another chat interface sitting on top of their data,” said Voxel51 Product Manager Adonai Vera. “They need an agent that can maintain context across the model development lifecycle and orchestrate actions across the full data flywheel.”
Nebius and Voxel51 partner to connect the physical AI data and compute stack
Nebius and Voxel51 address two of the hardest infrastructure problems in physical AI: compute and data.
Nebius provides predictable performance and reliable cloud infrastructure as an integrated system engineered for AI, while Voxel51 helps teams turn large volumes of raw recordings into model-ready datasets.
Together, the companies are hosting a series of hands-on workshops where developers can run Voxel51 workflows on Nebius AI Cloud. The goal is to help teams build a tighter physical AI data flywheel while spending less time stitching together the underlying data and compute stack.
“Physical AI is the next major frontier for AI because it brings digital intelligence into the world of atoms,” said Evan Helda, Head of Physical AI at Nebius. “But getting there will take more than better models. Robotics teams need the compute, cloud platform, and data infrastructure to turn every deployment, failure and edge case into a faster next iteration. That’s the kind of foundation we’re building with partners like Voxel51.”
About Voxel51
Voxel51 is an end-to-end data platform for physical AI, helping teams turn complex multimodal datasets into better AI models. The platform unifies search, visualization, curation, annotation, and evaluation, with AI-powered workflows that automate data-intensive tasks, while giving developers control over their models and infrastructure. Voxel51 is trusted by teams at Berkshire Grey, Ford, Porsche, and Precision Planting to develop AI systems that operate in the physical world.
